Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](United Therapeutics)"
Count: 131
Selected: 0
| NCT ID | Title |
|---|
| NCT02893995 | Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension | ||
| NCT02882126 | An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension | ||
| NCT05776225 | Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection | ||
| NCT05255991 | Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | ||
| NCT05203510 | A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension | ||
| NCT05060315 | Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin | ||
| NCT04905693 | Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | ||
| NCT04708782 | Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | ||
| NCT04084678 | A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH | ||
| NCT03950739 | Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso | ||
| NCT03888365 | Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH | ||
| NCT03857841 | A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD | ||
| NCT03794583 | Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD) | ||
| NCT03683186 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | ||
| NCT03626688 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | ||
| NCT03497689 | EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension | ||
| NCT03496623 | A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) | ||
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | ||
| NCT03055234 | Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) | ||
| NCT03055221 | TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH) | ||
| NCT03045029 | ADAPT - A Patient Registry of the Real-world Use of Orenitram® | ||
| NCT03043651 | Open-label Extension of Oral Treprostinil in Subjects With PH Associated With HFpEF | ||
| NCT03037580 | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction | ||
| NCT03016468 | Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH | ||
| NCT03012646 | Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD | ||
| NCT02999906 | Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension | ||
| NCT02847260 | Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID) | ||
| NCT02693171 | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients | ||
| NCT02633293 | An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE | ||
| NCT02630316 | Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE | ||
| NCT02603068 | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis | ||
| NCT02318758 | Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers | ||
| NCT02279745 | Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension | ||
| NCT02279160 | Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension | ||
| NCT02276872 | Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years | ||
| NCT02261883 | Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn | ||
| NCT02149095 | Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers | ||
| NCT01934582 | A Pharmacokinetic Substudy of the TDE-PH-304 Protocol | ||
| NCT01884038 | Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients | ||
| NCT01799473 | Tyvaso Dosing and Titration Evaluation: TyTRATE Registry | ||
| NCT01795950 | Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH) | ||
| NCT01746485 | Three Times Daily Dosing of UT-15C | ||
| NCT01592045 | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma | ||
| NCT01588405 | Remodulin® to Oral Treprostinil Transition | ||
| NCT01560637 | An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension | ||
| NCT01560624 | Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy | ||
| NCT01557660 | Inhaled Treprostinil for PAH: Open-label Extension | ||
| NCT01557647 | Safety and Efficacy of Inhaled Treprostinil in Patients With PAH | ||
| NCT01477333 | Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso® | ||
| NCT01266265 | Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies |
